Anti-Inflammatory

[THE GENERAL 1,982]

Meloxicam

[paulus 26]

 

the human equivalent is often far cheaper and identical

If your talking about ibuprofen mate that's a no no .........

 

no, the human equivalent is meloxicam

[paulus 26]

Meloxicam

correct

[skycat 6,173]

Metacam can be and is used long term in the palliative care of older dogs: in other words, it will eventually f*ck the liver, but in an old dog with limited life left, it's a good option.

[wi11ow 2,657]

30 years ive used Ibuprofen no problems

[Squirrel_Basher 17,100]

not been available that long mate

[wi11ow 2,657]

The most effective and useful of these was ibuprofen, which Boots began to sell in 1964 in the United Kingdom as the prescription medication Brufen.

Read more: http://www.discoveriesinmedicine.com/Hu-Mor/Ibuprofen.html#ixzz33MsWV0jr

 

 

 

 

i wouldt say it if i never

[TOPPER 1,809]

ibuprofen is poisonus to dogs , theres far better stuff on the market for dogs all anti inflam s if used long term attack the liver and kidneys there a quick fix to be honest , vets love metacam as its a good money maker , [ il give fluffy a little injection to calm her down] kerching another £30 on the bill and the best bit is it wasnt needed ithe first place

[andy26 618]

You can get 180 ml bottles of metacam for 40 quid which is quit good I think

[BIGLURKS 874]

I must off got ripped for the last bottle I got it was 60 notes from my vets

[Rabbit Hunter 6,613]

What would people recommend as a better alternative to metacam that will do the same job?

[THE GENERAL 1,982]

What would people recommend as a better alternative to metacam that will do the same job?

Read the previous comments.

[Corkonian 44]

I prefer to use Rimadyl - I always just use the tablet version.

 

Note I have one dog that appears to get a bit of a rash from it so it won't suit every animal. Always watch carefully for any side effects when using any medicine.

Some info from the makers here -

https://www.rimadyl.com/account/DisplayPDF?docName=PI.pdf

ANIMAL SAFETY STUDIES: Laboratory studies in unanesthetized dogs and clinical field studies have demonstrated that Rimadyl is well
tolerated in dogs after oral administration.
In target animal safety studies, Rimadyl was administered orally to healthy Beagle dogs at 1, 3, and 5 mg/lb twice daily (1, 3 and 5 times the recommended total daily dose) for 42 consecutive days with no significant adverse reactions. Serum albumin for a single female dog receiving 5 mg/lb twice daily decreased to 2.1 g/dL after 2 weeks of treatment, returned to the pre-treatment value (2.6 g/dL) after 4 weeks of treatment, and was 2.3 g/dL at the final 6-week evaluation. Over the 6-week treatment period, black or bloody stools were observed in 1 dog (1 incident) treated with 1 mg/lb twice daily and in 1 dog (2 incidents) treated with 3 mg/lb twice daily. Redness of the colonic mucosa was observed in 1 male that received 3 mg/lb twice daily.
Two of 8 dogs receiving 10 mg/lb orally twice daily (10 times the recommended total daily dose) for 14 days exhibited hypoalbuminemia. The mean albumin level in the dogs receiving this dose was lower (2.38 g/dL) than each of 2 placebo control groups (2.88 and 2.93 g/dL, respectively). Three incidents of black or bloody stool were observed in 1 dog. Five of 8 dogs exhibited reddened areas of duodenal mucosa on gross pathologic examination. Histologic exam of these areas revealed no evidence of ulceration, but did show minimal congestion of the lamina propria in 2 of the
5 dogs.
In separate safety studies lasting 13 and 52 weeks, respectively, dogs were administered orally up to 11.4 mg/lb/day (5.7 times the recommended total daily dose of 2 mg/lb) of carprofen. In both studies, the drug was well tolerated clinically by all of the animals. No gross or histologic
changes were seen in any of the treated animals. In both studies, dogs receiving the highest doses had average increases in serum L-alanine aminotransferase (ALT) of approximately 20 IU.
In the 52-week study, minor dermatologic changes occurred in dogs in each of the treatment groups but not in the control dogs. The changes were described as slight redness or rash and were diagnosed as non-specific dermatitis. The possibility exists that these mild lesions were treatment related, but no dose relationship was observed.
Clinical field studies were conducted with 549 dogs of different breeds at the recommended oral doses for 14 days (297 dogs were included in
a study evaluating 1 mg/lb twice daily and 252 dogs were included in a separate study evaluating 2 mg/lb once daily). In both studies the drug
was clinically well tolerated and the incidence of clinical adverse reactions for Rimadyl-treated animals was no higher than placebo-treated animals (placebo contained inactive ingredients found in Rimadyl). For animals receiving 1 mg/lb twice daily, the mean post-treatment serum
ALT values were 11 IU greater and 9 IU less than pre-treatment values for dogs receiving Rimadyl and placebo, respectively. Differences were not statistically significant. For animals receiving 2 mg/lb once daily, the mean post-treatment serum ALT values were 4.5 IU greater and 0.9 IU less than pre-treatment values for dogs receiving Rimadyl and placebo, respectively. In the latter study, 3 Rimadyl-treated dogs developed a 3-fold or greater increase in (ALT) and/or (AST) during the course of therapy. One placebo-treated dog had a greater than 2-fold increase in ALT. None of these animals showed clinical signs associated with laboratory value changes. Changes in the clinical laboratory values (hematology and clinical chemistry) were not considered clinically significant. The 1 mg/lb twice daily course of therapy was repeated as needed at 2-week intervals in 244 dogs, some for as long as 5 years.
Clinical field studies were conducted in 297 dogs of different breeds undergoing orthopedic or soft-tissue surgery. Dogs were administered
2 mg/lb of Rimadyl 2 hours prior to surgery then once daily, as needed for 2 days (soft tissue surgery) or 3 days (orthopedic surgery). Rimadyl was well tolerated when used in conjunction with a variety of anesthetic-related drugs. The type and severity of abnormal health observation in Rimadyl- and placebo-treated animals were approximately equal and few in number (see Adverse Reactions). The most frequent abnormal health observation was vomiting and was observed at approximately the same frequency in Rimadyl- and placebo-treated animals. Changes in clinicopathologic indices of hematopoetic, renal, hepatic, and clotting function were not clinically significant. The mean post-treatment serum ALT values were 7.3 IU and 2.5 IU less than pre-treatment values for dogs receiving Rimadyl and placebo, respectively. The mean post-treatment AST values were 3.1 IU less for dogs receiving Rimadyl and 0.2 IU greater for dogs receiving placebo.
Clinical field studies on the use of Rimadyl Injectable were conducted on 331 dogs undergoing orthopedic or soft tissue surgery. Dogs were administered 2 mg/lb of Rimadyl subcutaneously 2 hours prior to surgery and once daily thereafter, as needed, for 2 days (soft tissue surgery) or 3 days (orthopedic surgery). Rimadyl was well tolerated when used in conjunction with a variety of anesthetic-related drugs. The type and severity of abnormal health observations in Rimadyl- and placebo-treated animals were approximately equal and few in number (see Adverse Reactions). The most frequent abnormal health observation was vomiting and was observed at approTxAimKaEteTlIyMthEe same frequency in Rimadyl- and placebo-treated animals. Changes in clinicopathologic indices of hematopoetic, renal, hepatic, and clotting function were not clinically significant. The mean post- treatment serum ALT values were 8.4 IU and 7.0 IU less than pre-treatment values for dogs receiving Rimadyl and placebo, respectively. The mean post-treatment AST values were 1.5 IU and 0.7 IU greater for dogs receiving Rimadyl and placebo, respectively.